Literature DB >> 30394725

A Perspective on Nanoparticle Universal Influenza Vaccines.

Lei Deng1, Bao-Zhong Wang1.   

Abstract

Annually recurring seasonal influenza causes massive economic loss and poses severe threats to public health worldwide. The current seasonal influenza vaccines are the most effective means of preventing influenza infections but possess major weaknesses. Seasonal influenza vaccines require annual updating of the vaccine strains. However, it is an unreachable task to accurately predict the future circulating strains. Vaccines with mismatched strains dramatically compromise the vaccine efficacy. In addition, the seasonal influenza vaccines are ineffective against an unpredictable pandemic. A universal influenza vaccine would overcome these weaknesses of the seasonal vaccines and abolish the threat of influenza pandemics. One approach under investigation is to design influenza vaccine immunogens based on conserved, type-specific amino acid sequences and conformational epitopes, rather than strain-specific. Such vaccines can elicit broadly reactive humoral and cellular immunity. Universal influenza vaccine development has intensively employed nanotechnology because the structural and morphological properties of nanoparticles dramatically improve vaccine immunogenicity and the induced immunity duration. Layered protein nanoparticles can decrease off-target immune responses, fine-tune antigen recognition and processing, and facilitate comprehensive immune response induction. Herein, we review the designs of effective nanoparticle universal influenza vaccines, the recent discoveries of specific nanoparticle features that contribute to immunogenicity enhancement, and recent progress in clinical trials.

Entities:  

Keywords:  headless hemagglutinin; long-lasting; matrix protein 2; prophylaxis; self-assembling; virus-like particle

Mesh:

Substances:

Year:  2018        PMID: 30394725     DOI: 10.1021/acsinfecdis.8b00206

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  10 in total

1.  Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice.

Authors:  Ye Wang; Lei Deng; Gilbert X Gonzalez; Latika Luthra; Chunhong Dong; Yao Ma; Jun Zou; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Adv Healthc Mater       Date:  2019-12-15       Impact factor: 9.933

2.  Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.

Authors:  Chunhong Dong; Bao-Zhong Wang
Journal:  Adv Nanobiomed Res       Date:  2021-12-07

Review 3.  Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins.

Authors:  Seyed Davoud Jazayeri; Chit Laa Poh
Journal:  Vaccines (Basel)       Date:  2019-11-01

Review 4.  Nano/microparticle Formulations for Universal Influenza Vaccines.

Authors:  Dylan A Hendy; Eva A Amouzougan; Isabella C Young; Eric M Bachelder; Kristy M Ainslie
Journal:  AAPS J       Date:  2022-01-07       Impact factor: 3.603

Review 5.  Progress towards the Development of a Universal Influenza Vaccine.

Authors:  Wen-Chien Wang; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Viruses       Date:  2022-07-30       Impact factor: 5.818

6.  Enhanced Immunogenicity of an Influenza Ectodomain Matrix-2 Protein Virus-like Particle (M2e VLP) Using Polymeric Microparticles for Vaccine Delivery.

Authors:  Keegan Braz Gomes; Ipshita Menon; Priyal Bagwe; Lotika Bajaj; Sang-Moo Kang; Martin J D'Souza
Journal:  Viruses       Date:  2022-08-30       Impact factor: 5.818

Review 7.  Flu Universal Vaccines: New Tricks on an Old Virus.

Authors:  Ruikun Du; Qinghua Cui; Lijun Rong
Journal:  Virol Sin       Date:  2020-09-01       Impact factor: 4.327

Review 8.  Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases.

Authors:  Lev A Dykman
Journal:  Expert Rev Vaccines       Date:  2020-04-28       Impact factor: 5.217

Review 9.  Progress in the Development of Universal Influenza Vaccines.

Authors:  Wenqiang Sun; Tingrong Luo; Wenjun Liu; Jing Li
Journal:  Viruses       Date:  2020-09-17       Impact factor: 5.048

10.  Development of PDA Nanoparticles for H9N2 Avian Influenza BPP-V/BP-IV Epitope Peptide Vaccines: Immunogenicity and Delivery Efficiency Improvement.

Authors:  Yongqing Liu; Xiaoli Wang; Jiangfei Zhou; Shuaibing Shi; Tengfei Shen; Liangliang Chen; Min Zhang; Chengshui Liao; Chen Wang
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.